IL13 and atopic eczema: The targeted IL-13 inhibitors (tralokinumab, lebrikizumab, cendakimab, and eblasakimab) have been approved for the treatment of moderate to severe atopic dermatitis, offering treatment efficacy, safety, persistence over time, and a significant improvement in pruritus and quality of life.